AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2024
Feb 5, 2024
31523_dirs_2024-02-05_581a24c0-88a3-4419-80c6-ecd087bc2a7d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2024-02-01
Reporting Person: Campbell Bradley L (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-01 | Common Stock | M | 7500 | $8.61 | Acquired | 882886 | Direct |
| 2024-02-01 | Common Stock | M | 8333 | $12.28 | Acquired | 891219 | Direct |
| 2024-02-01 | Common Stock | S | 15833 | $12.5597 | Disposed | 875386 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-01 | Stock Options (right to buy) | $8.61 | M | 7500 | Disposed | 2025-01-02 | Common Stock (7500) | Direct |
| 2024-02-01 | Stock Options (right to buy) | $12.28 | M | 8333 | Disposed | 2025-06-01 | Common Stock (8333) | Direct |
Footnotes
F1: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.45 to $12.74 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: All of the options were fully vested and exercisable as of the transaction date.